View in EDS

Mirikizumab as Induction and Maintenance Therapy in Chinese Patients with Ulcerative Colitis: A Subpopulation Analysis of the Randomized, Global Phase 3 LUCENT-1 and LUCENT-2 Trials.

Saved in:
Bibliographic Details
Title: Mirikizumab as Induction and Maintenance Therapy in Chinese Patients with Ulcerative Colitis: A Subpopulation Analysis of the Randomized, Global Phase 3 LUCENT-1 and LUCENT-2 Trials.
Authors: Ran Z; Shanghai University of Medicine and Health Sciences Affiliated Zhoupu Hospital, Shanghai, China., Chen Y; The Second Affiliated Hospital Zhejiang University School of Medicine, Hangzhou, China., Miao Y; The First Affiliated Hospital of Kunming Medical University, Kunming, China., Wang Y; West China Hospital of Sichuan University, Chengdu, China., Gao X; The Sixth Affiliated Hospital of Sun Yat-sen University, Guangzhou, China., Zhong J; Shanghai Jiaotong University School of Medicine Ruijin Hospital, Shanghai, China., Ding X; The Affiliated Hospital of Qingdao University, Qingdao, China., Wang C; The First Affiliated Hospital of Fujian Medical University, Fuzhou, China., Zhang X; The Second Hospital of Hebei Medical University, Shijiazhuang, China., Ding Y; The Renmin Hospital of Wuhan University, Wuhan, China., Hu N; The First Affiliated Hospital of Anhui Medical University, Hefei, China., Tang D; Eli Lilly and Company, Shanghai, China., Yu J; Eli Lilly and Company, Shanghai, China., Qian C; Eli Lilly and Company, Shanghai, China., Shen J; School of Medicine, Renji Hospital, Shanghai Jiao Tong University, Shanghai, China. shenjun@vip.163.com.
Source: BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy [BioDrugs] 2026 Jul; Vol. 40 (4), pp. 733-745. Date of Electronic Publication: 2026 May 12.
Publication Type: Journal Article; Randomized Controlled Trial; Clinical Trial, Phase III
Journal Info: Publisher: Adis, Springer International Country of Publication: New Zealand NLM ID: 9705305 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1179-190X (Electronic) Linking ISSN: 11738804 NLM ISO Abbreviation: BioDrugs Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 42120652
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Mirikizumab as Induction and Maintenance Therapy in Chinese Patients with Ulcerative Colitis: A Subpopulation Analysis of the Randomized, Global Phase 3 LUCENT-1 and LUCENT-2 Trials.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Ran+Z%22">Ran Z</searchLink>; Shanghai University of Medicine and Health Sciences Affiliated Zhoupu Hospital, Shanghai, China.<br /><searchLink fieldCode="AU" term="%22Chen+Y%22">Chen Y</searchLink>; The Second Affiliated Hospital Zhejiang University School of Medicine, Hangzhou, China.<br /><searchLink fieldCode="AU" term="%22Miao+Y%22">Miao Y</searchLink>; The First Affiliated Hospital of Kunming Medical University, Kunming, China.<br /><searchLink fieldCode="AU" term="%22Wang+Y%22">Wang Y</searchLink>; West China Hospital of Sichuan University, Chengdu, China.<br /><searchLink fieldCode="AU" term="%22Gao+X%22">Gao X</searchLink>; The Sixth Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.<br /><searchLink fieldCode="AU" term="%22Zhong+J%22">Zhong J</searchLink>; Shanghai Jiaotong University School of Medicine Ruijin Hospital, Shanghai, China.<br /><searchLink fieldCode="AU" term="%22Ding+X%22">Ding X</searchLink>; The Affiliated Hospital of Qingdao University, Qingdao, China.<br /><searchLink fieldCode="AU" term="%22Wang+C%22">Wang C</searchLink>; The First Affiliated Hospital of Fujian Medical University, Fuzhou, China.<br /><searchLink fieldCode="AU" term="%22Zhang+X%22">Zhang X</searchLink>; The Second Hospital of Hebei Medical University, Shijiazhuang, China.<br /><searchLink fieldCode="AU" term="%22Ding+Y%22">Ding Y</searchLink>; The Renmin Hospital of Wuhan University, Wuhan, China.<br /><searchLink fieldCode="AU" term="%22Hu+N%22">Hu N</searchLink>; The First Affiliated Hospital of Anhui Medical University, Hefei, China.<br /><searchLink fieldCode="AU" term="%22Tang+D%22">Tang D</searchLink>; Eli Lilly and Company, Shanghai, China.<br /><searchLink fieldCode="AU" term="%22Yu+J%22">Yu J</searchLink>; Eli Lilly and Company, Shanghai, China.<br /><searchLink fieldCode="AU" term="%22Qian+C%22">Qian C</searchLink>; Eli Lilly and Company, Shanghai, China.<br /><searchLink fieldCode="AU" term="%22Shen+J%22">Shen J</searchLink>; School of Medicine, Renji Hospital, Shanghai Jiao Tong University, Shanghai, China. shenjun@vip.163.com.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%229705305%22">BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy</searchLink> [BioDrugs] 2026 Jul; Vol. 40 (4), pp. 733-745. <i>Date of Electronic Publication: </i>2026 May 12.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article; Randomized Controlled Trial; Clinical Trial, Phase III
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Adis%2C+Springer+International%22">Adis, Springer International </searchLink><i>Country of Publication: </i>New Zealand <i>NLM ID: </i>9705305 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1179-190X (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2211738804%22">11738804 </searchLink><i>NLM ISO Abbreviation: </i>BioDrugs <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=42120652
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1007/s40259-026-00776-y
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 733
    Titles:
      – TitleFull: Mirikizumab as Induction and Maintenance Therapy in Chinese Patients with Ulcerative Colitis: A Subpopulation Analysis of the Randomized, Global Phase 3 LUCENT-1 and LUCENT-2 Trials.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Ran Z
      – PersonEntity:
          Name:
            NameFull: Chen Y
      – PersonEntity:
          Name:
            NameFull: Miao Y
      – PersonEntity:
          Name:
            NameFull: Wang Y
      – PersonEntity:
          Name:
            NameFull: Gao X
      – PersonEntity:
          Name:
            NameFull: Zhong J
      – PersonEntity:
          Name:
            NameFull: Ding X
      – PersonEntity:
          Name:
            NameFull: Wang C
      – PersonEntity:
          Name:
            NameFull: Zhang X
      – PersonEntity:
          Name:
            NameFull: Ding Y
      – PersonEntity:
          Name:
            NameFull: Hu N
      – PersonEntity:
          Name:
            NameFull: Tang D
      – PersonEntity:
          Name:
            NameFull: Yu J
      – PersonEntity:
          Name:
            NameFull: Qian C
      – PersonEntity:
          Name:
            NameFull: Shen J
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 07
              Text: 2026 Jul
              Type: published
              Y: 2026
          Identifiers:
            – Type: issn-electronic
              Value: 1179-190X
          Numbering:
            – Type: volume
              Value: 40
            – Type: issue
              Value: 4
          Titles:
            – TitleFull: BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy
              Type: main
ResultId 1